Sibold William John

CEO William John Sibold sold 1,663 shares of MDGL at $431.94 for $718.3K; stock down -28.2% from 52-week high

William John Sibold, President and CEO, sold 1,663 shares on 2026-03-06 at $431.94, reducing his holdings from 163.5K to 161.8K shares (-1.0% reduction). The stock is currently -28.2% from its 52-week high and down -9.6% over the past 30 days. Notably, at the same ticker (MDGL), Sibold's prior 5 sales show mixed timing: only 1 of 4 measurable prior sales was well-timed at the 90-day mark, suggesting inconsistent predictive power specific to this company. His cross-ticker track record shows an average 90d return after sells of +17.9%, indicating his prior sales generally preceded stock appreciation, not declines. The company remains unprofitable with a $-114.2M annual net income despite strong $287.3M quarterly revenue and 432% annual growth, creating fundamental tension between growth trajectory and current losses.

MDGL CEO Sibold William John sold 1,577 shares at $492.42 on 2026-01-26 (776.5K value); stock near 52-week low, down 17.2% from peak

CEO Sibold William John sold 1,577 shares of MADRIGAL PHARMACEUTICALS, INC. at $492.42, representing a small 1.1% reduction of his 150,074-share position. The sale occurs as MDGL trades at $499.17, down 16.6% over the past 30 days and 17.2% below its 52-week high of $602.83. At MDGL specifically, his prior four measurable same-ticker sales showed only 1 of 4 well-timed at the 90-day mark, suggesting limited predictive value in his historical sales pattern at this ticker. The company remains unprofitable with $-114.2M net income on $287.3M quarterly revenue, providing a contrasting fundamental backdrop to the stock's recent weakness. Without additional context regarding planned or scheduled sales, the transaction itself is modest in scale, but the cumulative price decline warrants investor attention to underlying business momentum.

CEO Sibold William John sold 2,400 shares of MDGL at $575.34 (Dec 4, 2025); holds 150,074 post-sale.

Sibold William John, President and CEO of Madrigal Pharmaceuticals, sold 2,400 shares for $1,380,816.00 at $575.34, reducing his holdings by 1.6% to 150,074 shares. The sale occurred near the 52-week high ($601.03), with the stock currently trading at $586.21, only 2.5% below peak. At this ticker, Sibold has executed 5 prior open-market sales; reviewing his timing record at MDGL, his sales have been measurably well-timed only 1 of 4 times at the 90-day mark (25%), with recent sales in August 2025 capturing gains after (+38.9%, +38.6% respectively). Notably, the company reported a net loss of $-114,190,000.00 in the latest quarter and was unprofitable over the full fiscal year, creating a backdrop of operational underperformance despite strong 90-day stock appreciation of +35.4%. The timing of this sale near a peak price, combined with persistent unprofitability, merits investor attention to whether management views the recent rally as unsustainable.

MDGL CEO Sibold sells 7,279 shares for $3.2M as stock rallies 29.8% in 30d; unprofitable company.

William John Sibold, President and CEO, sold 7,279 shares of MADRIGAL PHARMACEUTICALS at $445.63 on 2025-09-09, reducing his holdings from 109,753 to 102,474 shares and realizing $3,243,740.77. The sale occurs against a backdrop of significant recent momentum: the stock has gained 29.8% over the past 30 days and 52.4% over the past 90 days, now trading at $448.73, only 1.1% below its 52-week high of $453.80. At the same-ticker level, Sibold's prior four trades at MDGL show mixed outcomes—a January 2025 sale followed by a small gain (+0.3% in 30d) then a decline (-4.6% in 90d), and a September 2024 sale that fell initially (-13.5% in 30d) before recovering (+31.6% in 90d). The company remains unprofitable (net income of $-42.3M against revenue of $212.8M in the latest quarter) and posted a negative full-year result. The timing of this insider sale near the 52-week high, combined with the company's ongoing losses despite its market valuation of $10.0B, warrants attention to whether the stock's steep recent gains reflect sustainable fundamentals or valuations disconnected from profitability.

CEO Sibold sells 7,616 shares for $3,047,756.37 at $400.18 blended avg; stock near 52-week high at $407.09

William John Sibold, President and CEO of Madrigal Pharmaceuticals, executed 2 separate sales totaling 7,616 shares for $3,047,756.37 on 2025-08-21 at a blended average price of $400.18, reducing his holdings from 117,369 shares to 109,753 shares (a 6.5% reduction). The sale occurred as the stock trades at $407.09, at the top of its 52-week range ($202.48–$407.09), and following a sharp 90-day advance of +52.2%. Against his cross-ticker track record of 2 prior sells with an average 90-day return of +13.5% and a 50.00% well-timed rate, the current timing pattern at MDGL itself is mixed—his 2 prior sales at this ticker showed 1 well-timed outcome (90d return of +31.6% in September 2024) and 1 poorly timed (90d return of -4.6% in January 2025). The company remains unprofitable, with latest quarter revenue of $212,802,000.00 and net income of -$42,281,000.00 against a $9.1B market cap, providing limited fundamental support for valuations near 52-week highs.

Sibold (President/CEO) sold 1,584 shares of MDGL at $335.24 on 2025-01-24 for $531.0K; holds 54.3K shares post-sale.

Sibold's sale of 1,584 shares (-2.8% of pre-transaction holdings) occurred at $335.24, near the 52-week high of $354.85, as the stock has declined 12.4% from that peak and currently trades at $310.92. His cross-ticker track record shows 1 prior sell with an average 90-day return of +31.6%, indicating that sale was poorly-timed (the stock rose after he sold). At MDGL specifically, his prior 2024-09-09 sell saw the stock gain +31.6% over 90 days, and the same pattern holds here—a poorly-timed sale when measured against subsequent price movement. Against the backdrop of a fundamentally challenged company with $-107.0M net income over its most recent full fiscal year, a CEO selling near cyclical highs (within 5.5% of the 52-week peak) warrants investor attention, though the small reduction in his 54.3K-share post-transaction stake limits the directional signal.

MDGL CEO Sibold sells 6,363 shares for $1.6M as stock falls 20.5% from 52-week high amid losses

Sibold William John, President and CEO of Madrigal Pharmaceuticals, sold 6,363 shares at $243.83 on 2024-09-09 for $1,551,490.29, reducing his holdings from 62,250 shares to 55,887 shares. This sale occurs against a backdrop of significant operational challenges: the company reported a net income of $-151,971,000.00 for its most recent full fiscal year, and the stock has declined 20.5% from its 52-week high of $292.96, with a 90-day decline of 15.9%. The sale represents a 10.2% reduction in his prior holdings, executed at a price point substantially above the current market price of $233.00. The company remains unprofitable despite a market capitalization of $5,059,053,741.00, and Sibold's discretionary reduction of shareholdings during a period of sustained price decline and operational losses warrants close monitoring of near-term developments and company guidance.